Introduction
============

Systemic infection triggers a spectrum of metabolic and behavioral changes, termed sickness behavior, which includes fever, lethargy, hypophagia, anhedonia. Sickness behavior is an evolutionarily conserved response to illness and represents a reprioritization by the organism to conserve energy and maximize the probability of recovery ([@B17]). Systemic administration of the bacterial endotoxin lipopolysaccharide (LPS) can induce sickness behavior in humans ([@B62]; [@B22]) and rodents ([@B73]; [@B9]) and despite not readily crossing the blood-brain barrier ([@B3]), LPS increases central proinflammatory cytokines including interleukin (IL)-1β and tumor necrosis factor (TNF)-α ([@B73]; [@B52]; [@B66]), and alters local field potential ([@B64]; [@B48]). Peripheral inflammatory status is communicated to the brain via direct vagal signaling to the brainstem and hypothalamus; macrophage activation in the circumventricular organs lacking a patent BBB, leading to secretion of inflammatory mediators into the parenchyma; and activation of endothelial cyclooxygenases to secrete lipophilic prostaglandins directly into the parenchyma ([@B18]). Manipulation of prostaglandin-dependent mechanisms revealed neuroanatomical pathways underpinning sickness responses ([@B61]), but the molecular basis for acute LPS-induced suppression of activity is poorly understood.

Sickness behavior sometimes encompasses cognitive impairment: peripheral LPS or IL-1β administration can affect synaptic plasticity and hippocampal-dependent learning and memory ([@B81]), although the relative preservation of cognitive function is striking given the overt suppression of spontaneous behavior ([@B14]; [@B67]). However, when inflammatory insults are severe, or occur in older age or during evolving dementia, they may induce delirium ([@B23]). Delirium is an acute onset and fluctuating syndrome characterized by inability to sustain attention, reduced awareness and perception, and profound cognitive impairment ([@B2]), affecting ∼1/5 hospital inpatients (or 1/3 for those \>80 years age; [@B59]). Delirium is associated with extended hospitalization, subsequent cognitive decline, and increased risk for dementia, but the neurobiological understanding of delirium is limited.

We have modeled delirium, using superimposition of LPS on models of neurodegeneration ([@B26]; [@B53]; [@B15]; [@B46]) to produce acute onset, fluctuating deficits in relevant cognitive domains ([@B19]). These LPS-associated deficits are absent in normal animals but susceptibility to LPS-induced cognitive impairment increases as a function of the underlying neurodegenerative state of the brain ([@B31]; [@B19]). LPS-induced deficits are prostaglandin dependent and can be mimicked by systemic administration of IL-1β ([@B31]) or TNF-α ([@B36]) and reduced by systemic administration of IL-1 receptor antagonist (IL-1RA; [@B14]; [@B67]), suggesting that IL-1β may affect cognition via a peripheral route. One possibility is that acute sickness impinges on cerebral metabolism through systemic metabolic changes; cerebral glucose uptake is reduced in a rat model of LPS-induced sepsis ([@B64]), carbohydrate metabolism is decreased post-LPS ([@B40]), and IL-1 has been demonstrated to induce hypoglycemia ([@B20]). Systemic hypoglycemia impacts on central glucose levels ([@B41]), which in turn can affect neuronal activity and may be especially detrimental if the brain is already compromised during evolving neurodegenerative pathology.

Therefore, we hypothesized that LPS-induced disturbances in glucose metabolism would drive suppression of activity and cognitive impairment in mice. We assessed locomotor activity and working memory, while manipulating glucose metabolism with LPS, 2-deoxyglucose (2-DG), and insulin to determine effects of altered glycemic status on sickness behavior and cognitive impairments in disease-naive and ME7 mice. Finally, we analyzed carbohydrate metabolism in the cerebrospinal fluid (CSF) of inflammatory trauma (hip fracture) patients to assess brain energy metabolites in humans with inflammation-induced delirium. The findings show that altered glycemic status causes disruption of brain function in mice and that brain carbohydrate metabolism is also disrupted during delirium in patients.

Materials and Methods
=====================

### Animals

Female c57BL/6J aged five to eight months (Harlan), mixed sex IL-1R1^−/−^ mice (six months) and mixed sex c57BL/6J aged 8--12 weeks (in-house colony) were housed at 21°C with a 12/12 h light/dark cycle (lights on 8 A.M. to 8 P.M.) with food and water available *ad libitum*. All animal experiments were in accordance with European Commission Directive 2010/63/EU and were performed following ethical approval by the TCD Animal Research Ethics Committee and licensing by the Health Products Regulatory Authority (HPRA).

### ME7 prion model of neurodegeneration

Mice were anaesthetized using Avertin (2,2,2-tribromoethanol 50% w/v in tertiary amyl alcohol, diluted 1:40 in H~2~O; 20 ml/kg, i.p.; Sigma) and placed in a stereotaxic frame (David Kopf Instruments). A total of 1 μl of 10% w/v ME7-infected c57BL/6J or 10% w/v normal brain homogenate (NBH) in sterile PBS was infused into the dorsal hippocampus at −2.0 mm (A/P), ±1.6 mm (M/L), −1.7 mm (D/V) from Bregma as described previously ([@B52], [@B53]). Mice recovered in a heated chamber, then returned to their home cage where their drinking water was supplemented with sucrose (5% w/v) and carprofen (0.05% v/v; Rimadyl, Pfizer).

### Treatments

Mice were injected intraperitoneally with one or a combination of the following treatments using sterile saline as a vehicle: LPS from *Salmonella equine abortus* (100 or 250 µg/kg; Sigma), IL-1β (25 µg/kg; R&D Systems), IL-1RA (10 mg/kg; Kineret, Biovitrum), glucose (2 g/kg; Sigma), 2-DG (2 g/kg; Sigma), and insulin \[11.5 IU/kg (400 µg/kg); Sigma\]. LPS was administered 2 h before open field behavior (Except where noted as 5 hours) and 3 h before the T-maze task. Glucose was administered 30 min before any behavioral task.

### Body temperature

Body temperature was measured in mixed sex c57BL/6J (8--12 weeks old) by subcutaneous transponders (IPTT300; BioMedic Data Systems) that were implanted under isoflurane using a custom-designed injector. The temperature was checked every 20 min with BMDS Smart Probes 7000 series Reader (BioMedic Data Systems) starting from 1 h before the saline or LPS challenge up to 240 min after the treatment.

### Behavioral assessment

Spontaneous activity was assessed by observing locomotor activity in an open field as previously described ([@B54]). Briefly, mice were allowed to freely and individually explore an open field arena (58 × 33 × 19 cm), which was divided into squares (10 × 10 cm). Over the course of 3 min, the number of squares crossed by each mouse was counted.

Cognitive performance was assessed using an escape-from-water alternation task in a paddling T-maze as described previously ([@B53]; [@B67]). Briefly, this working memory task involves two runs per trial. On the first run, mice only have one of the T-maze arms available to them, which has an exit at the end of it to escape from the shallow water. On the second run, mice are given a choice between the two arms with the exit now in the opposite arm to the first run. Mice were trained (two blocks/day, five trials/block, two runs/trial) until they performed with at ≥80% success. They were then pharmacologically challenged and tested on the same day of the challenge. There were three blocks of five trials postchallenge \[corresponding to 3--5 (+3), 5--7 (+5), and 7--9 (+7) h postchallenge\] and two blocks for insulin, due to its rapid action on blood glucose \[corresponding to 40--160 min (+1 h) and 160--300 min (+3 h) postchallenge\]. All mice underwent recovery testing (two blocks of five trials) on the following day.

### Blood glucose measurements

For serial blood measurements, mice were placed in a plastic restrainer, the tail vein was dilated using warm water and lanced using a 30-G needle. Glucose was measured using a veterinary glucometer (AlphaTRAK 2, Zoetis), which assesses glucose concentration based on oxidation by flavin adenine dinucleotide (FAD) glucose dehydrogenase. This enzyme preferentially accepts glucose as substrate but shows 2-DG oxidation at 37% of the rate of glucose oxidation. However, at a dose 0.0003 mol 2-DG/25-g mouse, this 2-DG is insufficient to affect blood glucose (∼10 m[m]{.smallcaps}) determination. Terminal blood glucose measurements were made following sodium pentobarbital overdose and incising the right ventricle, immediately before transcardial perfusion. Blood glucose readings were higher on the veterinary glucometer compared with a clinical glucometer (data not shown), but basal levels were broadly in line with other studies ([@B20], [@B21]; [@B10]; [@B75]).

### CSF sampling and analysis

In mice, CSF was collected under terminal anesthesia. Mice were placed in a stereotaxic frame and the cisterna magna accessed by lowering the incisor bar on the animal\'s head to angle it downwards at 45° from horizontal. Using a small volume insulin syringe (BD Micro - Fine + 0.3 ml Insulin Syringe Demi), a freehand puncture was performed slowly to avoid brain stem damage and blood contamination. Approximately 5 μl was collected in 0.5-ml microcentrifuge tubes.

### Hip fracture patient cohort

Hip fracture is a frequent occurrence in frail, elderly populations. Delirium occurs with high prevalence in these patients ([@B49]), and since these patients, in many centers, receive spinal anesthesia for hip fracture repair surgery, this offers an opportunity for CSF collection allowing assessment of the impact of this acute inflammatory trauma on CSF markers of brain energy metabolism in older individuals. CSF was collected from hip fracture patients acutely admitted to Oslo University Hospital after informed consent from the patient and/or proxy (if patients were unable to consent due to cognitive impairment), as approved by the Regional Committee for Medical and Health Research Ethics (South-East Norway; REK 2009/450). The presence of delirium was assessed in all participants using the Confusion Assessment Method (CAM; [@B39]) based on a 10- to 30-min interview with participants and information from relatives, nurses, and hospital records. One geriatrician and one old age psychiatrist independently evaluated whether participants met the ICD-10 criteria for dementia before the fracture, based on all available data, as explained earlier ([@B80]). CSF was collected in propylene tubes at the onset of spinal anesthesia. Samples were centrifuged, aliquoted and stored at --80°C, as previously described ([@B79]).

Samples were defrosted and transferred to CMA Microvials (CMA Microdialysis AB). In mice, there were two occasions where sample volumes were too small (\<3 μl) for analysis. In these cases, two samples from the same treatment groups were pooled (see [Fig. 2](#F2){ref-type="fig"}*H*,*I*). All other mouse CSF measurements were made on samples taken from individual mice. Glucose, lactate, and pyruvate (the latter in humans only) concentrations were determined using a CMA600 Microdialysis Analyzer (CMA Microdialysis AB). The CMA600 uses a colorimetric analysis technique to detect these analytes. Using glucose as an example, the CMA reagent works by metabolism of glucose by glucose oxidase to form its gluconic acid and hydrogen peroxide. The hydrogen peroxide then reacts with phenol to produce a color change and this is detected by a photometric sensor. While 2-DG (used as a treatment in some mice that undergo this analysis) can react with glucose oxidase, its reactivity is much lower than that of glucose (V~max~ around 50 vs glucose 1150 M s^−1^; [@B30]). In practice, 2-DG treatment has no significant effect on CSF glucose readings based on our data (see [Fig. 2](#F2){ref-type="fig"}*K*). Basal levels of CSF glucose were in the range expected from other studies ([@B37]; [@B55]; [@B71]), as was the case for CSF lactate ([@B37]). The lower limits of detection were: glucose (0.1 mmol/l), lactate (0.1 mmol/l), and pyruvate (4 μmol/l). Since the ability to detect pyruvate is an indication of its concentration, non-detected samples probably represent very low concentrations of pyruvate. However, samples where no value was returned by the assay were assigned the value of 2 μmol/l (i.e., 50% of the lowest value that we did detect) as a conservative measure.

### Experimental design and statistical analyses

Statistical analysis was performed in GraphPad Prism 5 and IBM SPSS version 25. Pairs of groups were measured using *t* tests, and all multiple comparisons were made using ANOVAs, paired and repeated measure variants were used as appropriate. Full statistical analyses and experimental numbers are included in figure legends. Where data were found to violate the assumptions of *t* tests (using a combination of visual inspection, Kolmogorov--Smirnov and the Shapiro--Wilk normality tests), the non-parametric Mann--Whitney *U* test was used instead. The group numbers, statistical tests used, and test values are all summarized in [Table 1](#T1){ref-type="table"}.

###### 

Summary of experimental design and statistical analyses used in this study

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Figure                        Group (*n*)                                      Test used                                     Statistical values                                          *p* value   *Post hoc* tests
  ----------------------------- ------------------------------------------------ --------------------------------------------- ----------------------------------------------------------- ----------- -----------------------------------------------------------
  [1](#F1){ref-type="fig"}*B*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    Treatment~(saline;LPS)~\                                    \<0.0001\   Bonferroni\
                                Saline at 2 h (8)\                                                                             *F*~(1,22)~ = 36.71\                                        0.0236\     LPS vs saline at 2 h:\
                                Saline at 4 h (6)\                                                                             Time~(2,4\ h)~\                                             0.0236      *t* = 6.215; *p* \< 0.001\
                                LPS at 2 h (6)\                                                                                *F*~(1,22)~ = 5.916\                                                    LPS vs saline at 4 h:\
                                LPS at 4 h (6)                                                                                 Treatment × time\                                                       *t* = 2.483; *p* \< 0.05
                                                                                                                               *F*~(1,22)~ = 5.916                                                     

  [1](#F1){ref-type="fig"}*C*   *c57BL6* mice:\                                  2 × 5 repeated measures ANOVA                 Treatment~(saline;LPS)~\                                    0.0005\     Bonferroni\
                                Saline (6)\                                                                                    *F*~(1,44)~ = 24.10\                                        0.0019\     LPS vs saline at 5 h:\
                                LPS (7)                                                                                        Time~(0,3,5,7,24\ h)~\                                      0.0276      *t* = 3.362; *p* \< 0.01\
                                                                                                                               *F*~(4,44)~ = 5.054\                                                    LPS vs saline at 7 h:\
                                                                                                                               Treatment × time\                                                       *t* = 4.575; *p* \< 0.001
                                                                                                                               *F*~(4,44)~ = 3.019                                                     

  [1](#F1){ref-type="fig"}*D*   *c57BL6* mice:\                                  3 × 6 repeated measures ANOVA                 Treatment~(saline;IL-1β,IL-1RA10μg)~\                       0.0420\     Bonferroni\
                                Saline+saline (6)\                                                                             *F*~(2,85)~ = 3.843\                                        \<0.0001\   IL-1β+Sal vs Sal+Sal 1 h:\
                                IL-1β+saline (7)\                                                                              Time~(0,1,3,5,7,24\ h)~\                                    0.0008      *t* = 3.566; *p* \< 0.01\
                                IL-1β+IL-1RA~10\ µg~ (7)                                                                       *F*~(5,85)~ = 19.39\                                                    IL-1β+Sal vs Sal+Sal 3 h:\
                                                                                                                               Treatment × time\                                                       *t* = 3.409; *p* \< 0.01\
                                                                                                                               *F*~(10,85)~ = 3.442                                                    IL-1β+Sal v IL-1β+IL-1RA 3 h: *t* = 3.013; *p* \< 0.05

  [1](#F1){ref-type="fig"}*E*   LPS/IL-1 in WT, IL-1RI^−/−^ mice\                2 × 3 between groups ANOVA                    Genotype~(c57;1L-1R1)~\                                     0.0972\     Bonferroni\
                                c57BL6+saline (6)\                                                                             *F*~(1,29)~ = 2.938\                                        \<0.0001\   Between genotypes:\
                                c57BL6+LPS (6)\                                                                                Treatment~(saline;LPS;IL-1β)~\                              0.0785      IL-1β -- c57BL6 v IL-1R1^−/−^\
                                c57BL6+ IL-1β (5)\                                                                             *F*~(2,29)~ = 21.81\                                                    *t* = 2.836; *p* \< 0.05\
                                IL-1R1^−/−^+saline (6)\                                                                        Genotype × treatment\                                                   Within genotypes:\
                                IL-1R1^−/−^+LPS (6)\                                                                           *F*~(2,29)~ = 2.782                                                     c57BL6 -- LPS vs Sal\
                                IL-1R1^−/−^+IL-1β (6)                                                                                                                                                  *t* = 4.287; *p* \< 0.001\
                                                                                                                                                                                                       c57BL6 -- IL-1β vs Sal\
                                                                                                                                                                                                       *t* = 2.465; *p* \< 0.05\
                                                                                                                                                                                                       IL-1R1^−/−^ -- LPS vs Sal\
                                                                                                                                                                                                       *t* = 4.763; *p* \< 0.001

  [1](#F1){ref-type="fig"}*F*   LPS in WT, IL-1R1^−/−^\                          2 × 2 repeated measures ANOVA                 Genotype~(c57;1L-1R1)~\                                     0.0385\     Bonferroni\
                                c57BL6+LPS (7)\                                                                                *F*~(1,40)~ = 5.673\                                        \<0.0001\   No significant differences between genotypes at any time.
                                IL-1R1^−/−^+LPS (5)                                                                            Time~(0,1,3,5,7,24\ h)~\                                    0.2324      
                                                                                                                               *F*~(4,40)~ = 22.78\                                                    
                                                                                                                               Genotype × time\                                                        
                                                                                                                               *F*~(4,40)~ = 1.460                                                     

  [1](#F1){ref-type="fig"}*G*   IL-1RA-treated^-^ mice:\                         3 × 5 repeated measures ANOVA                 Treatment~(Sal;IL-1β,IL-1RA10μg)~\                          \<0.0001\   Bonferroni\
                                Saline+saline (12)\                                                                            *F*~(2,132)~ = 16.18\                                       \<0.0001\   Between treatments:\
                                LPS+saline (12)\                                                                               Time~(0,2,4,6,24\ h)~\                                      0.0011      LPS+Sal vs Sal+Sal 2 h\
                                LPS+IL-1RA~10~ (12)                                                                            *F*~(4,132)~ = 39.08\                                                   *t* = 3.449; *p* \< 0.01\
                                                                                                                               Treatment × time\                                                       LPS+Sal vs Sal+Sal 4 h\
                                                                                                                               *F*~(8,132)~ = 3.502                                                    *t* = 5.160; *p* \< 0.001\
                                                                                                                                                                                                       LPS+Sal vs Sal+Sal 6 h\
                                                                                                                                                                                                       *t* = 4.319; *p* \< 0.001\
                                                                                                                                                                                                       LPS+IL-1RA vs Sal+Sal 4 h: *t* = 4.551; *p* \< 0.001\
                                                                                                                                                                                                       LPS+IL-1RA~10~ vs Sal+Sal 6 h: *t* = 3.817; *p* \< 0.001

  [2](#F2){ref-type="fig"}*A*   *c57BL6* mice:\                                  6 × 2 repeated measures ANOVA                 Treatment~(saline;LPS)~\                                    0.0075\     Bonferroni\
                                LPS (8)\                                                                                       *F*~(1,14)~ = 9.74\                                         \<0.0001    LPS vs Sal at 4 h\
                                Saline (8)                                                                                     Time~(−60,40,120,240,420\ min,\ 24\ h)~\                                *t* = 3.576; *p* \< 0.050\
                                                                                                                               *F*~(3,40)~ = 11.09                                                     LPS vs Sal at 7 h\
                                                                                                                                                                                                       *t* = 4.456; *p* \< 0.010

  [2](#F2){ref-type="fig"}*B*   *c57BL6* mice:\                                  14 × 2 repeated measures ANOVA                Time~(−60−240\ min,every\ 20\ min)~\                        0.0082\     Bonferroni\
                                LPS (5)\                                                                                       *F*~(3,24)~ = 5.166\                                        0.4502      No significant differences between treatments at any time
                                Saline (6)                                                                                     Treatment:\                                                             
                                                                                                                               *F*~(1,9)~ = 0.6231                                                     

  [2](#F2){ref-type="fig"}*C*   *c57BL6* mice:\                                  3 × 2 repeated measures ANOVA                 Treatment~(saline;LPS)~\                                    0.0207\     Bonferroni\
                                LPS (8)\                                                                                       *F*~(1,18)~ = 6.43\                                         \<0,0001    LPS vs Sal at 5 h\
                                Saline (12)                                                                                    Time~(0,5,24\ h)~\                                                      *t* = 6.854; *p* \< 0.0001
                                                                                                                               *F*~(1,22)~ = 29.46                                                     

  [2](#F2){ref-type="fig"}*D*   *c57BL6* mice:\                                  3 × 2 repeated measures ANOVA                 Treatment~(saline;LPS)~\                                    0,0062\     Bonferroni\
                                LPS (8)\                                                                                       *F*~(1,15)~ = 10.11\                                        0,0035      LPS vs Sal at 5 h\
                                Saline (12)                                                                                    Time~(0,5,24\ h)~\                                                      *t* = 3.122; *p* \< 0.05
                                                                                                                               *F*~(1,20)~ = 9.458                                                     

  [3](#F3){ref-type="fig"}*A*   *c57BL6* mice:\                                  Linear regression                             Saline: slope = −3.512 ± 7.51*; r*^2^ = 0.01790\            0.6484\     
                                Saline (14)\                                                                                   LPS: slope = 9.121 ± 2.439*; r*^2^ = 0.4824                 0.0020      
                                LPS (14)                                                                                                                                                               

  [3](#F3){ref-type="fig"}*B*   *c57BL6* mice:\                                  2 × 3 repeated measures ANOVA                 Treatment~(saline;LPS)~\                                    0.4025\     Bonferroni\
                                (movement)\                                                                                    *F*~(1,16)~ = 0.7815\                                       \<0.0001\   Between treatments:\
                                Saline (5)\                                                                                    Movement~(spontaneous;prompted;total)~\                     0.0007      Spontaneous: LPS vs Sal\
                                LPS (5)                                                                                        *F*~(2,16)~ = 43.20\                                                    *t* = 3.457; *p* \< 0.01\
                                                                                                                               Treatment × movement\                                                   Within treatments:\
                                                                                                                               *F*~(2,16)~ = 11.98                                                     LPS (Spont. vs prompt)\
                                                                                                                                                                                                       *t* = 7.060; *p* \< 0.001\
                                                                                                                                                                                                       LPS (Spont. vs total)\
                                                                                                                                                                                                       *t* = 8.015; *p* \< 0.001

  [3](#F3){ref-type="fig"}*D*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    LPS treatment~(saline;LPS)~\                                \<0.0001\   Bonferroni\
                                Saline+saline (7)\                                                                             *F*~(1,25)~ = 29.88\                                        0.3765\     Sal+Sal vs LPS+Sal\
                                Saline+glucose (7)\                                                                            Glucose treatment~(saline;glucose)~\                        0.6319      *t* = 3.580; *p* \< 0.01\
                                LPS+saline (8)\                                                                                *F*~(1,25)~ = 0.8106\                                                   Sal+glucose vs LPS+glucose\
                                LPS+glucose (7)                                                                                LPS × glucose\                                                          *t* = 4.142; *p* \< 0.001
                                                                                                                               *F*~(1,25)~ = 0.2352                                                    

  [3](#F3){ref-type="fig"}*D*   *c57BL6* mice:\                                  Unpaired *t* test, two-tailed                 *t*~(11)~ = 2.498                                           0.0296      
                                LPS+saline (8)\                                                                                                                                                        
                                LPS+Sal+2-DG (5)                                                                                                                                                       

  [3](#F3){ref-type="fig"}*E*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    LPS treatment~(saline;LPS)~\                                0.0011\     Bonferroni\
                                Saline+saline (7)\                                                                             *F*~(1,27)~ = 13.39\                                        0.2322\     Sal+Sal vs LPS+Sal\
                                Saline+glucose (7)\                                                                            Glucose treatment~(saline;glucose)~\                        0.0032      *t* = 4.813; *p* \< 0.001\
                                LPS+saline (8)\                                                                                *F*~(1,27)~ = 1.494\                                                    LPS+Sal vs LPS+glucose\
                                LPS+glucose (9)                                                                                LPS × glucose\                                                          *t* = 3.315; *p* \< 0.01
                                                                                                                               *F*~(1,27)~ = 10.48                                                     

  [3](#F3){ref-type="fig"}*E*   *c57BL6* mice:\                                  Unpaired *t* test, two-tailed                 *t*~(13)~ = 5.766                                           \<0.0001    
                                LPS+saline (8)\                                                                                                                                                        
                                LPS+Sal+2-DG (7)                                                                                                                                                       

  [3](#F3){ref-type="fig"}*F*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    LPS treatment~(Sal;LPS)~\                                   \<0.0001\   Bonferroni\
                                Saline+saline (7)\                                                                             *F*~(1,27)~ = 60.00\                                        0.0152\     Sal+Sal vs LPS+Sal\
                                Saline+glucose (7)\                                                                            Glucose treatment~(saline;glucose)~\                        0.3943      *t* = 6.010; *p* \< 0.001\
                                LPS+saline (8)\                                                                                *F*~(1,27)~ = 6.721\                                                    Sal+Gluc. vs LPS+Gluc.\
                                LPS+glucose (9)                                                                                LPS × glucose\                                                          *t* = 4.931; *p* \< 0.001\
                                                                                                                               *F*~(1,27)~ = 0.7495                                                    LPS+Sal vs LPS+glucose\
                                                                                                                                                                                                       *t* = 2.571; *p* \< 0.05

  [3](#F3){ref-type="fig"}*F*   *c57BL6* mice:\                                  Unpaired *t* test, two-tailed                 *t*~(13)~ = 2.567                                           0.0234      
                                LPS+saline (8)\                                                                                                                                                        
                                LPS+Sal+2-DG (7)                                                                                                                                                       

  [3](#F3){ref-type="fig"}*G*   *c57BL6* mice:\                                  2 × 6 repeated measures ANOVA                 Treatment~(LPS+saline;LPS+glucose)~\                        0.0272\     Bonferroni\
                                LPS+saline (6)\                                                                                *F*~(1,50)~ = 6.681\                                        \<0.0001\   Between treatments:\
                                LPS+glucose (6)                                                                                Time~(−1,2,4,6,18,24\ h)~\                                  \<0.0001    LPS+Sal vs LPS+glucose:2 h\
                                                                                                                               *F*~(5,50)~ = 32.95\                                                    *t* = 6.784; *p* \< 0.001\
                                                                                                                               Treatment × time\                                                       Within treatments:\
                                                                                                                               *F*~(5,50)~ = 9.029                                                     LPS+glucose, --1 vs 2 h\
                                                                                                                                                                                                       *t* = 4.730; *p* \< 0.001

  [3](#F3){ref-type="fig"}*H*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    LPS treatment~(saline;\ LPS)~\                              \<0.0001\   Bonferroni\
                                Saline+saline (7)\                                                                             *F*~(1,22)~ = 39.85\                                        0.0009\     Sal+Sal vs LPS+Sal\
                                Saline+glucose (5)\                                                                            Glucose treatment~(saline;\ glucose)~\                      0.9315      *t* = 4.235; *p* \< 0.001\
                                LPS+saline (4)\                                                                                *F*~(1,22)~ = 14.57\                                                    Sal+glucose vs LPS+glucose\
                                LPS+glucose (8)                                                                                LPS × glucose\                                                          *t* = 4.720; *p* \< 0.001\
                                                                                                                               *F*~(1,22)~ = 0.007560                                                  Sal+Sal vs Sal+glucose\
                                                                                                                                                                                                       *t* = 2.795; *p* \< 0.05\
                                                                                                                                                                                                       LPS+Sal vs LPS+glucose\
                                                                                                                                                                                                       *t* = 2.606; *p* \< 0.05

  [3](#F3){ref-type="fig"}*H*   *c57BL6* mice:\                                  Unpaired *t* test, two-tailed                 *t*~(7)~ = 3.367                                            0.0120      
                                LPS+saline (4)\                                                                                                                                                        
                                LPS+Sal+2-DG (4)                                                                                                                                                       

  [3](#F3){ref-type="fig"}*I*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    LPS treatment~(saline;LPS)~\                                0.1560\     Bonferroni\
                                Saline+saline (7)\                                                                             *F*~(1,21)~ = 2.165\                                        0.9276\     No analyses done: no main effects in ANOVA
                                Saline+glucose (5)\                                                                            Glucose treatment~(saline;glucose)~\                        0.5321      
                                LPS+saline (4)\                                                                                *F*~(1,21)~ = 0.008456\                                                 
                                LPS+glucose (7)                                                                                LPS × glucose\                                                          
                                                                                                                               *F*~(1,21)~ = 0.4037                                                    

  [3](#F3){ref-type="fig"}*J*   *c57BL6* mice:\                                  Unpaired *t* test, two-tailed                 *t*~(27)~ = 1.894                                           0.069       
                                Saline (13)\                                                                                                                                                           
                                2-DG (16)                                                                                                                                                              

  [3](#F3){ref-type="fig"}*K*   *c57BL6* mice:\                                  Mann--Whitney *U* test, two-tailed            *U* = 74.0                                                  0.1951      
                                Saline (13)\                                                                                                                                                           
                                2-DG (16)                                                                                                                                                              

  [4](#F4){ref-type="fig"}*A*   *c57BL6* mice:\                                  4 × 5 repeated measures ANOVA                 Treatment~(NBH+saline;NBH+LPS;ME7+saline;\ ME7+LPS)~\       \<0.0001\   Bonferroni\
                                NBH+saline (20)\                                                                               *F*~(3,288)~ = 19.08\                                       0.3351\     Between treatments:\
                                NBH+LPS (21)\                                                                                  Time~(−24,3,5,7,24\ h)~\                                    \<0.0001    NBH+LPS vs ME7+LPS\
                                ME7+saline (9)\                                                                                *F*~(4,288)~ = 1.146\                                                   3 h: *t* = 2.608; *p* \< 0.05\
                                ME7+LPS (26)                                                                                   Treatment × time\                                                       ME7+Sal vs ME7+LPS: 5 h: *t* = 4.933; *p* \< 0.001\
                                                                                                                               *F*~(12,288)~ = 4.999                                                   ME7+Sal vs ME7+LPS\
                                                                                                                                                                                                       7 h: *t* = 3.510; *p* \< 0.01

  [4](#F4){ref-type="fig"}*B*   *c57BL6* mice:\                                  2 × 3 between groups ANOVA                    Disease~(NBH;\ ME7)~\                                       0.0705\     Bonferroni\
                                NBH+saline (4)\                                                                                *F*~(1,20)~ = 3.649\                                        \<0.0001\   Between treatments:\
                                NBH+insulin~90~ (5)\                                                                           Treatment~(saline;insulin90min;insulin180min)~\             0.9581      NBH+Sal vs NBH+insulin~90~\
                                NBH+insulin~180~ (4)\                                                                          *F*~(2,20)~ = 17.11\                                                    *t* = 3.829; *p* \< 0.01\
                                ME7+saline (4)\                                                                                Disease × treatment\                                                    NBH+Sal vs NBH+insulin~180~\
                                ME7+insulin~90~ (4)\                                                                           *F*~(2,20)~ = 0.04292                                                   *t* = 3.447; *p* \< 0.01\
                                ME7+insulin~180~ (5)                                                                                                                                                   ME7+Sal vs ME7+insulin~90~\
                                                                                                                                                                                                       *t* = 3.756; *p* \< 0.01\
                                                                                                                                                                                                       ME7+Sal vs ME7+insulin~180~\
                                                                                                                                                                                                       *t* = 3.357; *p* \< 0.01

  [4](#F4){ref-type="fig"}*C*   *c57BL6* mice:\                                  2 × 3 between groups ANOVA                    Disease~(NBH;ME7)~\                                         0.7660\     Bonferroni\
                                NBH+saline (6)\                                                                                *F*~(1,28)~ = 0.09033\                                      \<0.0001\   Between Tx:\
                                NBH+insulin~90~ (5)\                                                                           Treatment~(saline;insulin90min;insulin180min)~\             0.8098      NBH+Sal vs NBH+insulin~90~\
                                NBH+insulin~180~ (4)\                                                                          *F*~(2,28)~ = 22.86\                                                    *t* = 4.691; *p* \< 0.001\
                                ME7+saline (10)\                                                                               Disease × treatment\                                                    ME7+Sal vs ME7+insulin~90~\
                                ME7+insulin~90~ (4)\                                                                           *F*~(2,28)~ = 0.2126                                                    *t* = 4.772; *p* \< 0.001
                                ME7+insulin~180~ (5)                                                                                                                                                   

  [4](#F4){ref-type="fig"}*D*   *c57BL6* mice:\                                  4 × 4 repeated measures ANOVA                 Treatment~(NBH+Sal;ME7+\ Sal;NBH+insulin;\ ME7+insulin)~\   0.0004\     Bonferroni\
                                NBH+saline (7)\                                                                                *F*~(3,135)~ = 7.418\                                       0.0002\     Between Tx:\
                                NBH+insulin (9)\                                                                               Time~(−24,1,3,24\ h)~\                                      0.0024      ME7+Sal v ME7+insulin:1 h\
                                ME7+saline (21)\                                                                               *F*~(3,135)~ = 6.986\                                                   *t* = 3.235; *p* \< 0.01\
                                ME7+insulin (12)                                                                               Treatment × time\                                                       ME7+Sal v ME7+insulin: 3 h\
                                                                                                                               *F*~(9,135)~ = 3.050                                                    *t* = 3.500; *p* \< 0.01

  [5](#F5){ref-type="fig"}*A*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    Disease~(NBH;ME7)~\                                         0.7803\     Bonferroni\
                                NBH+saline (10)\                                                                               *F*~(1,31)~ = 0.07914\                                      \<0.0001\   NBH+Sal vs NBH+LPS\
                                NBH+LPS (7)\                                                                                   Treatment~(saline;LPS)~\                                    0.3938      *t* = 7.011; *p* \< 0.001\
                                ME7+saline (11)\                                                                               *F*~(1,31)~ = 118.3\                                                    ME7+saline vs ME7+LPS\
                                ME7+LPS (7)                                                                                    Disease × treatment\                                                    *t* = 8.381; *p* \< 0.001
                                                                                                                               *F*~(1,31)~ = 0.7479                                                    

  [5](#F5){ref-type="fig"}*B*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    Disease~(NBH;ME7)~\                                         0.0170\     Bonferroni\
                                NBH+saline (5)\                                                                                *F*~(1,22)~ = 6.665\                                        \<0.0001\   NBH+Sal vs NBH+LPS\
                                NBH+LPS (7)\                                                                                   Treatment~(saline;LPS)~\                                    0.0708      *t* = 6.910; *p* \< 0.001\
                                ME7+saline (7)\                                                                                *F*~(1,22)~ = 146.5\                                                    ME7+Sal vs ME7+LPS\
                                ME7+LPS (7)                                                                                    Disease × treatment\                                                    *t* = 10.39; *p* \< 0.001\
                                                                                                                               *F*~(1,22)~ = 3.605                                                     NBH+Sal vs ME7+Sal\
                                                                                                                                                                                                       *t* = 3.033; *p* \< 0.05

  [5](#F5){ref-type="fig"}*C*   *c57BL6* mice:\                                  2 × 2 between groups ANOVA                    Disease~(NBH;ME7)~\                                         0.9917\     Bonferroni\
                                NBH+saline (5)\                                                                                *F*~(1,22)~ = 0.0001099\                                    0.6173\     No *post hoc*s performed
                                NBH+LPS (7)\                                                                                   Treatment~(saline;LPS)~\                                    0.9559      
                                ME7+saline (7)\                                                                                *F*~(1,22)~ = 0.2568\                                                   
                                ME7+LPS (7)                                                                                    Disease × treatment\                                                    
                                                                                                                               *F*~(1,22)~ = 0.003127                                                  

  [5](#F5){ref-type="fig"}*D*   ME7-inoculated *c57BL6* mice:\                   2 × 5 repeated measures ANOVA                 Treatment~(Sal+Sal;Sal+glucose;\ LPS+Sal;LPS+glucose)~\     \<0.0001\   Bonferroni\
                                Sal+Sal (12)\                                                                                  *F*~(3,240)~ = 13.57\                                       0.0046\     Between groups:\
                                Sal+glucose (13)\                                                                              Time~(−24,3,5,7,24\ h)~\                                    \<0.0001    3 h: LPS+Sal vs Sal+Sal\
                                LPS+Sal (20)\                                                                                  *F*~(4,240)~ = 3.865\                                                   *t* = 4.230; *p* \< 0.001\
                                LPS+glucose (19)                                                                               Treatment × time\                                                       5 h: LPS+Sal vs Sal+Sal\
                                                                                                                               *F*~(12,240)~ = 3.740                                                   *t* = 6.426; *p* \< 0.001\
                                                                                                                                                                                                       5 h: LPS+glucose vs LPS+sal\
                                                                                                                                                                                                       *t* = 3.543; *p* \< 0.01\
                                                                                                                                                                                                       5 h: Sal+glucose vs LPS+glucose\
                                                                                                                                                                                                       *t* = 2.826; *p* \< 0.05

  [6](#F6){ref-type="fig"}*A*   Hip fracture patients: Glucose\                  Mann--Whitney *U* test, two-tailed            *U* = 606.5                                                 0.8442      
                                No delirium (32)\                                                                                                                                                      
                                Delirium (39)                                                                                                                                                          

  [6](#F6){ref-type="fig"}*B*   Hip fracture pts: Lactate\                       Mann--Whitney *U* test, a priori one-tailed   *U* = 442.5                                                 0.0128      
                                No delirium (32)\                                                                                                                                                      
                                Delirium (40)                                                                                                                                                          

  [6](#F6){ref-type="fig"}*C*   Hip fracture pts: Lactate\                       Mann--Whitney *U* test, two-tailed            *U* = 1438                                                  0.2954      
                                No dementia (55)\                                                                                                                                                      
                                Dementia (59)                                                                                                                                                          

  [6](#F6){ref-type="fig"}*D*   Hip fracture pts: Pyruvate\                      Mann--Whitney *U* test, two-tailed            *U* = 514.5                                                 0.0494      
                                No delirium (32)\                                                                                                                                                      
                                Delirium (40)                                                                                                                                                          

  [6](#F6){ref-type="fig"}*E*   Hip fracture pts: Pyruvate\                      Fisher\'s exact test, two-sided                                                                           0.0306      
                                No delirium (32)\                                                                                                                                                      
                                Delirium (39)                                                                                                                                                          

  [6](#F6){ref-type="fig"}*F*   Hip fracture pts: Lactate/glucose ratio (LGR)\   Mann--Whitney *U* test, two-tailed            *U* = 399.5                                                 0.0048      
                                No delirium (32)\                                                                                                                                                      
                                Delirium (39)                                                                                                                                                          

  [6](#F6){ref-type="fig"}*G*   *c57BL6* mice (LGR)\                             2 × 2 between groups ANOVA                    Disease~(NBH;ME7)~\                                         0.1425\     Bonferroni\
                                NBH+saline (5)\                                                                                *F*~(1,22)~ = 2.313\                                        \<0.0001\   NBH+Saline vs NBH+LPS\
                                NBH+LPS (7)\                                                                                   Treatment~(saline;LPS)~\                                    0.9307      *t* = 4.580; *p* \< 0.001\
                                ME7+saline (7)\                                                                                *F*~(1,22)~ = 44.58\                                                    ME7+saline vs ME7+LPS\
                                ME7+LPS (7)                                                                                    Disease × treatment\                                                    *t* = 4.887; *p* \< 0.001
                                                                                                                               *F*~(1,22)~ = 0.007732                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results
=======

LPS and IL-1β both robustly reduce systemic glucose concentrations
------------------------------------------------------------------

The effects of systemic infection on spontaneous activity have largely been attributed to changes in cytokine signaling ([@B18]). IL-1 is reported to act at the endothelium or at forebrain targets to mediate LPS-induced suppression of motivated behaviors ([@B44]), but precisely how suppression of exploratory activity occurs is unclear. Here, we examined LPS-induced suppression of activity (see [Fig. 1](#F1){ref-type="fig"}*A*) and confirmed that LPS (250 μg/kg, i.p.) significantly increased plasma IL-1β levels at 2 and 6 h postchallenge in c57BL/6J mice compared with saline-treated controls ([Fig. 1](#F1){ref-type="fig"}*B*) and also reduced blood glucose levels by \>50% by 7 h postchallenge ([Fig. 1](#F1){ref-type="fig"}*C*). Blood glucose was decreased as early as 3 h following LPS and had not fully returned to baseline levels by 24 h. This reduction is not explained by suppression of feeding since blood glucose declines rapidly here ([Fig. 1](#F1){ref-type="fig"}*B*,*E*) but only begins to decrease after 6--12 h of fasting in healthy c57BL/6J mice ([@B11]).

![LPS and IL-1β significantly lower blood glucose concentrations. ***A***, Timeline for treatments and sampling times. Blood sampling was from tail vein, aside from the 24 hours (h) time point where glucose levels were measured from right atrial blood before transcardial perfusion. In one cohort, mice were euthanized at 2 and 6 h post-LPS challenge to collect plasma for the IL-1β Enzyme linked immunoabsorbent assay (ELISA). ***B***, LPS treatment (250 μg/kg, i.p.) significantly increased plasma IL-1β (*F*~(1,22)~ = 36.71; *p* \< 0.0001; *n* = 8 for saline/2 h group; *n* = 6 for other groups). ***C***, LPS treatment (*n* = 7) significantly reduced glucose levels over 24 h compared with saline controls (0.9%, i.p.; *n* = 6); main effect of treatment (*F*~(1,44)~ = 24.10; *p* = 0.0005). ***D***, IL-1β (25 μg/kg, i.p.; *n* = 7) reduced systemic glucose and IL-1β\'s effect can be blocked using IL-1RA (10 mg/kg, i.p.; *n* = 7). Main effect of treatment (*F*~(2,85)~ = 3.843; *p* = 0.0420); \*\*significantly lower glucose levels in IL-1β+saline-treated mice compared with controls (*n* = 6) at 1 and 3 h postchallenge. ***E***, c57BL/6J mice, both LPS (*n* = 6) and IL-1β (*n* = 5) significantly reduced blood glucose 4 h postchallenge versus saline controls (*n* = 6), while in IL-1R1^−/−^ mice, LPS (*n* = 6) but not IL-1 (*n* = 6) significantly reduced blood glucose versus controls (*n* = 6). Significant pairwise comparisons by Bonferroni *post hoc* test after a main effect of treatment (*F*~(2,29)~ = 21.81; *p* \< 0.0001) are annotated by \* (*p* \< 0.05) and \*\*\* (*p* \< 0.001). ***F***, Time course of changes in blood glucose in IL-1R1^−/−^ (*n* = 5) and c57BL/6J mice (*n* = 7; significant effect of genotype, *F*~(1,40)~ = 5.673; *p* = 0.0385, but no pairwise differences at any time point). ***G***, IL-1RA (10 mg/kg, *n* = 12) administered immediately after LPS treatment modestly attenuated LPS-induced reductions in glucose (*F*~(2,132)~ = 16.18; *p* \< 0.0001), but this was a transient effect (*F*~(4,132)~ = 39.08; *p* \< 0.001). There was a significant interaction of treatment and time (*F*~(8,132)~ = 3.502; *p* = 0.0011), and *post hoc* tests indicated that LPS+saline-treated mice (*n* = 12) had significantly lower blood glucose levels versus saline (*n* = 12) at 2, 4 and 6 h postchallenge, while LPS+IL-1RA (*n* = 12) did not significantly decrease glucose levels compared with controls until 4 h. All annotated Bonferroni *post hoc* tests were performed after significant main effects or interactions in ANOVA analysis: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. All data are expressed as mean ± standard error of the mean (SEM).](SN-JNSJ200225F001){#F1}

We investigated the contribution of IL-1β signaling to LPS-induced hypoglycemia. IL-1β (25 μg/kg, i.p.) reduced blood glucose, with a more rapid induction and earlier nadir than LPS ([Fig. 1](#F1){ref-type="fig"}*D*). IL-1β-induced reductions in glucose were completely blocked by IL-1RA (10 mg/kg i.p.). Therefore, IL-1β is sufficient to reduce systemic glucose levels.

To test whether IL-1β is necessary for LPS-induced hypoglycemia, we administered LPS (250 μg/kg, i.p.) and IL-1β (25 μg/kg, i.p.) to IL-1 receptor-1 knock-out (IL-1R1^−/−^) mice and c57BL/6J wild-type (WT) controls. Blood glucose measurements were taken 4 h postchallenge, to ensure robustly decreased glucose ([Fig. 1](#F1){ref-type="fig"}*C*,*D*). LPS and IL-1β again reduced blood glucose in WT mice. Although IL-1β-induced hypoglycemia was prevented in IL-1R1^−/−^ mice, LPS-induced reductions in glucose were statistically indistinguishable from those in WTs ([Fig. 1](#F1){ref-type="fig"}*E*). Moreover, the time course of LPS-induced glucose reduction was highly overlapping in WT and IL-1RI^−/−^ mice ([Fig. 1](#F1){ref-type="fig"}*F*). IL-1β antagonism with IL-1RA has been reported to attenuate LPS-induced hypoglycemia ([@B20]). Here, IL-1RA (10 mg/kg) showed only a very modest and temporary protective effect against 250 μg/kg LPS-induced decreases in glucose 2 h postchallenge and no effect thereafter, as detailed in [Figure 1](#F1){ref-type="fig"}*G*. Therefore, systemic IL-1β is sufficient to lower blood glucose, but it is not indispensable for LPS-induced decreases in glucose.

Blood glucose concentration is a major determinant of LPS-induced acute hypoactivity
------------------------------------------------------------------------------------

IL-1β has been reported as the major driver of sickness behavior ([@B50]; [@B18]). We sought to understand whether IL-1β signaling or decreases in glucose might be the proximate cause of LPS-induced hypoactivity. We first showed that LPS, at 250 µg/kg, intraperitoneally, produces an acute decrease in blood glucose, emerging from ∼2 h and statistically significant at 4 h (*p* = 0.0206) and 7 h (*p* = 0.0074), that temporally overlaps with acute suppression of locomotor activity (*p* = 0.0207) and rearing behavior (*p* = 0.0062). This hypoglycemia and inactivity are not occurring in the context of elevated body temperature, which does not change significantly during this period ([Fig. 2](#F2){ref-type="fig"}).

![The impact of systemically applied LPS on blood glucose, body temperature and activity. ***A***, Blood glucose. Effect of systemic LPS on blood glucose levels from 60 min before the challenge to 24 h after it. LPS (250 µg/kg, i.p.; *n* = 8) induced a significant decrease of blood glucose levels at 240 min (*p* = 0.0206) and 420 min (*p* = 0.007) when compared with vehicle-treated (Vh) animals (*n* = 8). Main effect of treatment (*F*~(1,14)~ = 9.74; *p* = 0.0075) and time (*F*~(3,40)~ = 11.09). No difference was found at 24 h after LPS (*p* = 0.66). ***B***, Body temperature. Effect of systemic LPS challenge (250 µg/kg, i.p.; *n* = 5) on body temperature as measured using subcutaneous temperature transponders. No differences were found when compared with vehicle-treated (Vh) animals (*n* = 6). Main effect of time (*F*~(3,24)~ = 5.166; *p* = 0.0082). ***C***, Open field distance. Effects of systemic LPS in the open field test. LPS (250 µg/kg, i.p.; *n* = 8) significantly decreased the traveled distance at 5 h (*p* \< 0.0001) when compared with vehicle-treated (Vh) group (*n* = 12). Main effect of treatment (*F*~(1,18)~ = 6.43; *p* = 0.0207) and time (*F*~(1,22)~ = 29.46; *p* \< 0.0001). ***D***, Open field rearing. Time spent rearing was significantly decreased by LPS (250 µg/kg, i.p.; *n* = 8) at 5 h (*p* = 0.0266) in comparison with vehicle-treated (Vh) mice (*n* = 12). Main effect of treatment (*F*~(1,15)~ = 10.11; *p* = 0.0062) and time (*F*~(1,20)~ = 9.458; *p* = 0.0035). All annotated Bonferroni *post hoc* tests were performed after significant main effects or interactions in ANOVA analysis: \**p* \< 0.05. All data are expressed as mean ± SEM.](SN-JNSJ200225F002){#F2}

LPS-induced hypoactivity in c57BL/6J mice (squares crossed/3 min) was significantly positively correlated with blood glucose levels ([Fig. 3](#F3){ref-type="fig"}*A*), with low blood glucose predicting low activity in LPS-treated mice (*r*^2^ = 0.4824, *p* = 0.002), while no significant correlation was present between blood glucose and activity in saline-treated animals. In a separate experiment, LPS-treated mice showed significantly less spontaneous activity in the open field compared with saline-treated controls but when inactive mice were prompted to move, using a gentle finger nudge, similar levels of activity were observed in both groups ([Fig. 3](#F3){ref-type="fig"}*B*) demonstrating that these animals are not unable to move or prevented from moving due to reduced energy availability. Rather, LPS-induced hypoactivity ([Fig. 3](#F3){ref-type="fig"}*A*) reflects reduced spontaneous activity. Moreover, the changes in blood glucose and activity are not dependent on changes in body temperature since parallel experiments ([Fig. 2](#F2){ref-type="fig"}*B*) demonstrated that body temperature was not significantly elevated under these conditions.

![Low blood glucose concentration drives LPS-induced hypoactivity. ***A***, Linear regression analyses of locomotor activity (squares crossed/3 min) versus blood glucose concentration (mmol/l) in animals challenged with saline (*n* = 14) and LPS (*n* = 17). Blood glucose concentrations significantly correlated with locomotor activity in LPS-treated mice. ***B***, LPS significantly reduces spontaneous activity in the open field compared with saline-treated controls. Prompting inactive mice to move by gently nudging them with a fingertip results in similar levels of activity, showing that LPS mice are capable of moving but are not motivated to do so. ***C***, Timeline for treatments and sampling times. Glucose (2 g/kg, i.p.) was administered 1.5 h post-LPS challenge (250 µg/kg, i.p.), and open field behavior was measured 2 h post-LPS challenge. Five minutes after open field testing, mice were euthanized, CSF samples taken, blood glucose levels assessed, and plasma collected for IL-1β ELISA. In one group, 2-DG (2 g/kg, i.p.) was given 3 h before LPS. ***D***, LPS (250 μg/kg, i.p.; *n* = 8) induced IL-1β production (*F*~(1,25)~ = 29.88; *p* \< 0.001), which was unaffected by glucose co-administration (*n* = 7; 90 min post-LPS) but blocked by 2-DG administration (intraperitoneal, *n* = 5, \#*p* = 0.0296 vs LPS+saline). ***E***, Locomotor activity was suppressed by LPS (main effect of LPS: *F*~(1,27)~ = 13.39; *p* = 0.0011) but rescued by glucose co-administration (interaction between treatments: *F*~(1,27)~ = 10.48; *p* = 0.0032); \*\*significant difference between LPS+glucose (*n* = 9) and LPS+saline (*n* = 8), and these were not significantly different to saline+saline (*n* = 7) or saline+glucose controls (*n* = 7). 2-DG+LPS completely suppressed locomotor activity in LPS-treated mice (*t*~(13)~ = 5.766; \#\#\#*p* \< 0.0001 vs LPS+saline). ***F***, Blood glucose was suppressed by LPS (main effect: *F*~(1,27)~ = 60.00; *p* \< 0.0001) and modestly increased by glucose (main effect: *F*~(1,27)~ = 6.721; *p* = 0.0152), and *post hoc* tests showed that LPS+glucose was significantly different to LPS+saline. ***G***, Glucose treatment 1.5 h after LPS provided significant but transient protection against LPS-induced hypoglycemia. ***H***, CSF (from the same animals) showed a main effect of LPS (*F*~(1,22)~ = 39.85; *p* \< 0.0001) and a strong main effect of glucose (*F*~(1,22)~ = 14.57; *p* = 0.0009). LPS+glucose was significantly different to LPS+saline in *post hoc* analysis (*p* \< 0.05). Two data points in these analyses represent two pooled samples each (in the saline+glucose and LPS+saline groups where some CSF samples were too low in volume to be assessed). They have been highlighted as slightly larger, filled symbols. ***I***, CSF lactate levels (same animals) were not altered by the treatments described. Again, the same samples were pooled for this analysis. In LPS-naive mice, 2-DG on its own does not significantly affect (***J***) spontaneous activity nor does it: have any effect on (***K***) blood glucose. Significance levels for Bonferroni *post hoc* tests: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. All data are expressed as mean ± SEM.](SN-JNSJ200225F003){#F3}

We then hypothesized that LPS-induced hypoactivity would be mitigated by treatment with glucose (2 g/kg, i.p.). In our experimental design ([Fig. 3](#F3){ref-type="fig"}*C*), we also included a separate group of mice that received LPS+2-DG, which inhibits glucose-6-phosphate isomerase to prevent glycolysis, which in turn blocks macrophage synthesis of IL-1β ([@B72]). LPS robustly produced IL-1β, reduced blood and CSF glucose levels, and suppressed activity ([Fig. 3](#F3){ref-type="fig"}*D--H*). Glucose treatment had no effect on IL-1β production ([Fig. 3](#F3){ref-type="fig"}*D*) but significantly improved locomotor activity ([Fig. 3](#F3){ref-type="fig"}*E*) and increased circulating glucose concentration ([Fig. 3](#F3){ref-type="fig"}*F*). Administering glucose to mice, following LPS treatment, only transiently protected against LPS-induced decreases in blood glucose levels ([Fig. 3](#F3){ref-type="fig"}*G*) as has previously been shown ([@B20]). In CSF, LPS significantly reduced glucose concentrations, and similar to the periphery, glucose treatment significantly protected against this ([Fig. 3](#F3){ref-type="fig"}*H*). However, CSF lactate remained statistically unchanged in all groups ([Fig. 3](#F3){ref-type="fig"}*I*). Therefore, LPS reduces CSF glucose concentration by ∼50%, and this can be mitigated by systemic glucose administration, with concomitant rescue of spontaneous activity. As predicted, 2-DG blocked LPS-induced IL-1β secretion ([Fig. 3](#F3){ref-type="fig"}*D*), and yet hypoactivity remained striking ([Fig. 3](#F3){ref-type="fig"}*E*). Therefore, animals with high IL-1β can remain spontaneously active if glucose concentration is temporarily boosted, and despite LPS producing no IL-1β when animals were additionally exposed to an inhibitor of glycolysis, these 2-DG-treated LPS animals show even less locomotor activity. These findings were replicated in a separate cohort of mice using a separate batch of LPS (100 μg/kg; i.p.; data not shown).

While 2-DG had a significant effect on spontaneous activity and blood glucose in LPS-treated mice, 2-DG on its own only modestly reduced locomotor activity ([Fig. 3](#F3){ref-type="fig"}*J*), and this decrease was not statistically significant (*t* = 1.894; df = 27, *p* = 0.069) in this normally distributed dataset. Likewise, 2-DG had no significant impact on blood glucose concentrations (Mann--Whitney, *U* = 74.00; *p* = 0.1951). However, these data were not normally distributed (failed 2/3 normality tests), and a small number of samples showed higher levels ([Fig. 3](#F3){ref-type="fig"}*K*). On subjective examination, mice receiving 2-DG alone did not appear sick but those showing the lowest activity post-2-DG tended to be those showing the highest levels of glucose, perhaps suggesting that blocking glucose utilization (functionally similar to hypoglycemia) could increase blood glucose but still produce inactivity as has been shown with higher doses of 2-DG ([@B77]).

Collectively, the data demonstrate that reduced glucose metabolism is a key proximate cause of LPS-induced suppression of spontaneous activity.

Neurodegeneration increases susceptibility to cognitive impairments due to reduced glucose availability
-------------------------------------------------------------------------------------------------------

We have previously shown, using the ME7 model, that evolving neurodegeneration progressively increases susceptibility to LPS-induced transient working memory impairments on a T-maze task ([@B53]; [@B67]). We replicate this here to illustrate the time course of these changes, and confirm that LPS does not produce such deficits in normal animals ([Fig. 4](#F4){ref-type="fig"}*A*). We hypothesized that this cognitive vulnerability in ME7 mice may be explained by a greater tendency toward metabolic insufficiency and that cognitive function in ME7 mice might be less able to cope with limiting glucose. We tested this hypothesis using insulin (11.5 IU/kg, i.p.), which significantly lowered blood glucose in both ME7 and NBH mice ([Fig. 4](#F4){ref-type="fig"}*B*). Basal levels of insulin were equivalent in ME7 and NBH mice, and all mice showed similar insulin pharmacokinetics on insulin treatment ([Fig. 4](#F4){ref-type="fig"}*C*). Despite this, and analogous to LPS-induced cognitive deficits ([Fig. 4](#F4){ref-type="fig"}*A*), insulin induced significant acute working memory dysfunction in ME7 mice that was absent in NBH controls ([Fig. 4](#F4){ref-type="fig"}*D*).

![Insulin-induced reductions in blood glucose produces acute cognitive dysfunction selectively in mice with prior neurodegeneration. ***A***, ME7 mice have a cognitive vulnerability under LPS treatment (*n* = 26) that was not present in NBH mice treated with LPS (*n* = 21). Saline does not induce cognitive deficits either in NBH (*n* = 20) or in ME7 (*n* = 9) mice. There was an interaction between treatment group and time (*F*~(12,288)~ = 5.00; *p* \< 0.0001). Blood glucose (mmol/l; ***B***) and plasma insulin concentrations (***C***) in saline-treated or insulin-treated (11.5 IU/kg, i.p.) NBH and ME7 mice. There were similar reductions in blood glucose (***B***, main effect of insulin, *F*~(2,20)~ = 17.11; *p* \< 0.0001) and equivalent insulin concentrations over 180 min in ME7 and NBH animals (***C***, main effect of insulin, *F*~(2,28)~ = 22.86; *p* \< 0.0001). ***D***, T-maze alternation in ME7 and NBH mice postchallenge with saline or insulin (+1 h = 40--160 min; and +3 h = 160--300 min postinsulin). Testing was performed earlier than in LPS-treated mice as insulin produces a more rapid decrease in blood glucose. There was a significant main effect of insulin (*F*~(3,135)~ = 7.418; *p* = 0.0004) and an interaction of ME7 and insulin (*F*~(9,135)~ = 3.050; *p* = 0.0024). ME7+insulin-treated mice (*n* = 12) had significantly lower alternation scores compared with NBH+saline controls (*n* = 7) at 1 and 3 h post-injection (NBH+insulin: *n* = 9; ME7+saline: *n* = 13). All data expressed as mean and standard error of the mean (SEM). Significance levels for Bonferroni post hoc tests: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](SN-JNSJ200225F004){#F4}

Given the ability of insulin-induced hypoglycemia to trigger cognitive deficits selectively in mice with existing neurodegenerative disease (ME7), we examined whether LPS produced differential hypoglycemic responses in NBH and ME7 animals. Mice were inoculated with ME7 or NBH and, 16 weeks later, challenged with saline or LPS (100 µg/kg, i.p.). LPS produced similar glucose reductions in NBH and ME7 mice in both blood ([Fig. 5](#F5){ref-type="fig"}*A*) and in CSF ([Fig. 5](#F5){ref-type="fig"}*B*), although baseline CSF glucose concentration was slightly higher in ME7 animals with respect to NBH. CSF lactate levels were similar in all four groups ([Fig. 5](#F5){ref-type="fig"}*C*). Since ME7 and NBH mice showed equivalent reduction in glucose, but differential cognitive outcomes post-LPS ([Fig. 4](#F4){ref-type="fig"}*A*), and because LPS-induced sickness behavior can be reversed byintraperitoneal glucose ([Fig. 3](#F3){ref-type="fig"}*E*), we hypothesized that the LPS-induced cognitive impairment in ME7 mice might be mediated by limiting glucose supply/utilization. ME7 mice were trained on the "escape from water" T-maze, until criterion performance of \>80% correct was achieved. They were then treated with saline or LPS (100 μg/kg, i.p.) and, 2.5 h after LPS, treated with saline or glucose (2 g/kg, i.p.) before undergoing T-maze testing. Neither saline-treated nor glucose-treated ME7 mice deviated from baseline T-maze performance in the absence of LPS, but LPS-treated ME7 mice showed robust impairment between 3--7 h post-LPS. Those impairments in ME7+LPS+saline mice were significantly attenuated by glucose applied 2.5 h after LPS (significant interaction of treatment and time: *F*~(12,240)~ = 3.740; *p* \< 0.0001; [Fig. 5](#F5){ref-type="fig"}*D*). Bonferroni *post hoc* analysis showed that ME7+LPS+glucose mice were significantly less impaired than ME7+LPS+saline mice at 5 h (*p* \< 0.01).

![LPS-induced cognitive dysfunction in mice with prior neurodegeneration can be ameliorated by glucose administration. After 5 h, LPS produced equivalent decrease in glucose concentration in blood (***A***) and CSF glucose in ME7 (*n* = 7) and NBH mice (*n* = 7; ***B***) compared with their respective saline-treated controls (*n* = 11 and *n* = 10, respectively). There were main effects of LPS on blood glucose (*F*~(1,31)~ = 118.3; *p* \< 0.0001) and on CSF glucose (*F*~(1,22)~ = 146.5; *p* \< 0.0001) and also an effect of disease on CSF glucose (*F*~(1,22)~ = 6.665; *p* = 0.0170), with ME7+saline \> NBH+saline by *post hoc* analysis. ***C***, There were no differences in CSF lactate levels. ***D***, T-maze alternation in ME7 mice postchallenge with saline or LPS, co-treated with glucose (2 g/kg) or saline. LPS+saline group (*n* = 20) showed robust cognitive impairment, but the LPS+glucose group (*n* = 19) showed significant attenuation. Two-way repeated measures ANOVA showed a main effect of LPS (*F*~(3,240)~ = 13.75; *p* \< 0.0001) and an interaction of LPS and glucose (*F*~(12,240)~ = 3.740; *p* \< 0.0001). LPS+glucose mice performed significantly better than the LPS+saline group at 5 h postchallenge (^\#\#^*p* \< 0.01). Significance levels for Bonferroni *post hoc* tests: \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001.](SN-JNSJ200225F005){#F5}

Human delirium triggered by acute inflammatory trauma (hip fracture) is associated with altered carbohydrate metabolism
-----------------------------------------------------------------------------------------------------------------------

Acute inflammation disrupted glucose metabolism and this caused acute cognitive dysfunction ([Fig. 5](#F5){ref-type="fig"}). We have previously demonstrated that this LPS-induced cognitive deficit is acute, transient, and fluctuating, occurs only in animals with prior degenerative pathology, and represents the best validated animal model of delirium superimposed on dementia ([@B19]; [@B63]). Therefore, seeking to investigate generalizability of these findings from mice, we assessed CSF concentrations of glycolytic metabolites in a cohort of acute hip fracture patients admitted for hip fracture repair with spinal anesthesia (for patient information, see [Table 2](#T2){ref-type="table"}). This represents an ideal cohort because CSF sampling is possible at the time of spinal anesthesia and because delirium occurs in a significant subset of these patients, and an acute inflammatory trauma (fracture) has been the proximate trigger for this delirium ([@B33]).

###### 

Demographic information for patients recruited to the study

                                                                                         No delirium (*n* = 32)   Prevalent delirium (*n* = 40)   *p* valued^[d](#TF2-4){ref-type="table-fn"}^                                     No dementia (*n* = 55)   Dementia (*n* = 59)   *p* value
  -------------------------------------------------------------------------------------- ------------------------ ------------------------------- ---------------------------------------------- --------------------------------- ------------------------ --------------------- -----------
  Median age, years (range)                                                              84.5 (60--93)            85 (68--95)                     0.69                                                                             84 (60--101)             86 (64--96)           0.25
  Male, *n* (%)                                                                          8 (25)                   11 (27.5)                       0.81                                                                             16 (29)                  15 (25)               0.66
  **Dementia, *n* (%)**^[a](#TF2-1){ref-type="table-fn"}^                                2 (6.3)                  32 (80)                         \<0.001                                        **Prevalent delirium, *n* (%)**   8 (15)                   32 (54)               \<0.001
  Independent in activities of daily living, *n* (%)^[b](#TF2-2){ref-type="table-fn"}^   23 (71.9)                8 (20)                          \<0.001                                                                          39 (71)                  7 (12)                \<0.001
  Living in an institution, *n* (%)                                                      3 (9.4)                  20 (50)                         \<0.001                                                                          3 (6)                    37 (63)               \<0.001
  APACHE II, median (IQR)^[c](#TF2-3){ref-type="table-fn"}^                              8 (6.3--9.8)             9 (8--11)                       0.004                                                                            8 (7--10)                9 (8--10)             0.76
  CCI, median (IQR)                                                                      1 (0--1.8)               1 (0--2)                        0.044                                                                            1 (0--2)                 1 (0--2)              0.58
  ASA score, median (IQR)                                                                2 (2--3)                 3 (3--3)                        \<0.001                                                                          3 (2--3)                 3 (2--3)              0.33

*^a^*Based on consensus in an expert panel.

*^b^*Defined as 19 or 20 points on Barthel activities of daily living.

*^c^*Without information on hematocrit and arterial blood gas.

*^d^*Mann--Whitney test and χ^2^ tests depending on data distribution.

APACHE II = acute physiology and chronic health evaluation II; ASA = American Society of Anesthesiologists Physical Health Classification; CCI = Charlson Comorbidity Index score; IQR = interquartile range. The columns on the left (no delirium vs prevalent delirium) contain all patients with prevalent delirium and those who never experienced delirium during their hospital stay. The columns on the right (no dementia vs dementia) contain a larger number of patients since they include also patients who were subsyndromal for delirium and those who may have experienced delirium at some later point in their hospitalization (but did not have delirium prevalent at the time of CSF sampling).

Hip fracture patients with ongoing delirium at the time of lumbar puncture ("prevalent delirium") were compared with those without any signs of delirium during hospital stay (preoperatively and postoperatively) on CSF glucose, lactate, and pyruvate (commonly used markers of central energy metabolism disturbance in clinical populations; [@B43]; [@B82]). CSF glucose was not different in those with and without delirium ([Fig. 6](#F6){ref-type="fig"}*A*). A previous study of all-cause delirium versus stable dementia ([@B8]) provided the a priori hypothesis that delirium would be associated with elevated lactate, and lactate was indeed significantly elevated during delirium (one-tailed Mann--Whitney analysis; *p* = 0.0128; [Fig. 6](#F6){ref-type="fig"}*B*). Changes in CSF lactate, associated with delirium, were not explained by dementia status. That is, comparing all patients with a diagnosis of dementia to all patients without dementia, in an expanded cohort (see [Table 2](#T2){ref-type="table"}), revealed that lactate levels in the CSF of hip fracture patients with dementia (*n* = 59), compared with age-matched patients with no dementia (*n* = 55), were not significantly different (*U* = 1438, *p* = 0.2954; [Fig. 6](#F6){ref-type="fig"}*C*). Median pyruvate levels were significantly elevated in delirium ([Fig. 6](#F6){ref-type="fig"}*D*). Although pyruvate was not detectable in CSF of all patients, it was detected significantly more often in patients with delirium ([Fig. 6](#F6){ref-type="fig"}*E*). The difference between delirium and no-delirium with respect to frequency of pyruvate detection was found to be significant (*p* = 0.0306) using the Fisher\'s exact test.

![Derangement of energy metabolism in human delirium. Metabolite levels in the CSF of hip fracture patients with delirium (*n* = 40) at the time of CSF sampling compared with age-matched patients with no delirium at any point of their hospital stay (*n* = 32). ***A***, Glucose levels in delirium (*n* = 39, one sample omitted due to a read error) and non-delirium cases were not significantly different (Mann--Whitney *U* = 606.5; *p* = 0.8442). ***B***, Patients with delirium had significantly higher levels of lactate in their CSF compared with controls (*U* = 442.5; *p* = 0.0128). ***C***, Lactate levels in the CSF of hip fracture patients with dementia (*n* = 59) at the time of CSF sampling compared with age-matched patients with no dementia (*n* = 55; no significant difference in CSF lactate *U* = 1438; *p* = 0.2954). ***D***, Patients with delirium showed significantly higher pyruvate levels compared with controls (*U* = 514.5; *p* = 0.0494), with all levels below the minimum detectable level (4 µmol/l) entered as 50% of this LOD (i.e., 2 µmol/ml). ***E***, In addition, pyruvate was detected significantly more often in patients with delirium compared with patients without delirium at time of CSF sampling (Fisher\'s exact test, *p* = 0.0306). ***F***, The LGR for patients with delirium (*n* = 39) was significantly higher compared with controls (*U* = 399.5; *p* = 0.0048). ***G***, LPS significantly increased the CSF LGR in both ME7 (*n* = 7) and NBH mice (*n* = 7) compared with their respective saline-treated controls (*n* = 7 and *n* = 5; *F*~(1,22)~ = 44.58; *p* \< 0.0001). Significance levels for Mann-Whitney U tests (***B***, ***D*** and ***F***) are annotated by \**p* \< 0.05, \*\**p* \< 0.01, for Fisher\'s exact test (***E***) by \**p* \< 0.05 and for Bonferroni post-hoc tests (***G***) by \*\*\**p* \< 0.001.](SN-JNSJ200225F006){#F6}

Increases in the CSF lactate:glucose ratio (LGR) have been associated with reduced consciousness ([@B60]) and increased mortality ([@B47]), and here, these data indicate an elevated LGR both in humans experiencing delirium after acute inflammatory trauma ([Fig. 6](#F6){ref-type="fig"}*F*) and in mice cognitively impaired by acute systemic inflammation ([Fig. 6](#F6){ref-type="fig"}*G*). The changes in LGR observed in mice and humans differ in how they arise, with an increase in the ratio driven by increases in lactate in humans ([Fig. 6](#F6){ref-type="fig"}*A*,*B*) and by decreases in glucose in the mouse ([Fig. 5](#F5){ref-type="fig"}*A*,*C*), but both mouse and human datasets indicate that there is a significant derangement of brain energy metabolism following these inflammatory insults, and in mice, this is clearly causal for acute cognitive dysfunction.

Discussion
==========

We demonstrate that LPS-induced hypoglycemia suppresses spontaneous activity in mice. Glycemic status was a major determinant of spontaneous activity after LPS. Reduced glucose availability also drove LPS-induced acute cognitive impairment in mice with underlying neurodegeneration and impairments were mitigated by exogenous glucose. The degenerating brain is also selectively vulnerable to cognitive disruption by insulin, despite equivalent blood glucose reductions. Finally, inflammatory trauma-induced delirium in humans was associated with altered central energy metabolism.

Hypoactivity
------------

Reducing blood glucose can be adaptive for the organism, depriving infectious agents of a key fuel source, and providing further glucose can actually increase *Listeria monocytogenes*-induced mortality ([@B78]). Nonetheless, we show, in the acute phase, that significant LPS-induced decreases in blood glucose reduce CSF glucose and suppress spontaneous activity. This is consistent with prior studies showing correlation between blood glucose and sickness behavior ([@B9]) and others showing that insulin-induced hypoglycemia suppresses social activity in c57BL/6 mice ([@B57], [@B58]). Here, by directly increasing glucose availability, by applying exogenous glucose, we prevented LPS-induced suppression of activity without reducing IL-1β. Moreover, 2-DG completely blocked LPS-induced IL-1β secretion, as previously shown for macrophage IL-1 production ([@B72]) but in also preventing glucose utilization it further suppressed activity. Although IL-1 is widely implicated in LPS-induced sickness behavior, LPS-induced hypoactivity persisted even when IL-1 secretion or action was blocked (IL-1RA, IL-1RI^−/−^). Although IL-1RA protection inhibited LPS-induced hypoglycemia in prior studies, those effects were partial: 100 µg IL-1RA/mouse marginally mitigated hypoglycemia ([@B20]), just as we observed here. IL-1RA (at 200 µg/mouse) completely blocked effects of 25 µg/kg IL-1β ([Fig. 1](#F1){ref-type="fig"}*D*), which leads to blood levels of ∼600 pg/ml IL-1β ([@B66]), and this IL-1RA dose should therefore block the effects of LPS-induced IL-1β (∼50--100 pg/ml; [@B73]; [@B52]; [@B66]). However, TNF-α also triggers hypoglycemia ([@B56]); thus, IL-1RA can have only a partial effect in limiting LPS-induced hypoglycemia. Therefore, while IL-1β might be a key mediator of hypoglycemia at 25 µg/kg LPS ([@B20]), IL-1RA barely limits hypoglycemia with LPS at 250 µg/kg (current study). Ultimately, the ability of glucose to restore activity in the current experiments reveals the importance of glucose uptake and use in fueling and regulating spontaneous activity under LPS-induced inflammation.

The hypothalamus monitors levels of circulating IL-1β ([@B50]) and glucose ([@B45]) and coordinates sickness behavior. IL-1β action in the hypothalamus is proposed to reprogram the organism to operate at lower circulating glucose levels after LPS (25 µg/kg; [@B20]), and these authors propose that IL-1β increases brain energy metabolism ([@B21]). \[^18^F\]-fluorodeoxyglucose (FDG-PET) experiments show that high-dose LPS (15 mg/kg) increased hypothalamic activity ([@B78]) but LPS (10 mg/kg, i.p.) has been shown to decrease glucose uptake across multiple cortical regions ([@B64]). If, as reported, IL-1 lowers the set-point for glucose homeostasis, allowing animals to function efficiently at lower glucose concentrations ([@B20], [@B21]; [@B4]), it is not intuitive why transiently increasing available glucose should rapidly increase spontaneous activity. Here, we show that administration of glucose raises both blood and CSF glucose ([Fig. 3](#F3){ref-type="fig"}), and although this "top-up" of glucose provides only temporary and partial increases in available glucose ([Fig. 3](#F3){ref-type="fig"}*G*; [@B20]), this is sufficient to restore spontaneous activity and cognition. We therefore propose that while the hypothalamus might be selectively active during acute inflammation, to coordinate neuroendocrine responses to the acute threat, the suppression of spontaneous locomotor activity that is actually observed may reflect decreased neural activity underpinned by decreased available glucose.

The neuroanatomical basis of LPS-induced suppression of exploratory activity is incompletely understood but correlates with suppression in cFOS in brain areas associated with positive motivation ([@B69]) and exploratory behavior ([@B29]). LPS triggers norepinephrine (NE) release in the hypothalamus ([@B27]) and lesioning caudal medullary NE inputs to the hypothalamus blocks LPS-induced hypoactivity ([@B29]). Hypoglycemia, hyperinsulinemia ([@B6]), and 2-DG treatment ([@B5]) all induce hypothalamic NE release, suggesting potential points of convergence for how inflammation and impaired glucose metabolism may drive changes in behavior during sickness.

Whatever the neuroanatomical and neurotransmitter underpinnings, the current data strongly support the idea that available and usable glucose is a key determinant of LPS-induced suppression of activity. This has implications for studies using peripheral LPS to examine theneurophysiological and behavioral consequences of systemic infection. Levels of circulating LPS arising from bolus LPS challenges are higher than in active infection ([@B16]). Bolus LPS treatment (4 ng/kg, i.v.) in human volunteers transiently decreases plasma glucose ([@B7]) while active infection typically does not produce hypoglycemia ([@B28]). Therefore, although bolus LPS would appear to have face validity as a model of systemic infection, if key behavioral and neurophysiological changes induced by LPS in experimental subjects are underpinned by a physiological change, i.e., hypoglycemia, that rarely occurs during active infection, this necessitates a review of the generalizability of bolus LPS-induced changes to understand changes during active infection.

Acute cognitive dysfunction and delirium
----------------------------------------

Human data suggest that reduced glucose uptake in the medial temporal lobe associates with impaired performance in hippocampal-dependent tasks ([@B35]). Remarkably, despite the robust and long lasting reductions in available glucose shown here, normal LPS-treated mice maintain good working memory ([Fig. 4](#F4){ref-type="fig"}; [@B67]). However, the same decreases in glucose, caused by LPS or insulin, were sufficient to triggerdysfunction in animals with prior neurodegeneration. Exogenously added glucose does not improve cognition in young rats ([@B42]) but enhances cognition in aged rats ([@B51]), supporting the idea that the same task may require additional metabolic support in aging/degenerating brain. We propose that the circuitry underpinning working memory may, during neurodegeneration, be operating close to thresholds for decompensation and may need to recruit additional brain areas to maintain this function. The addition of a further stressor may then be sufficient to unmask underlying vulnerability. Volunteers exposed to *Salmonella typhi* vaccination performed equally to controls on the Stroop test of executive function but recruited additional areas of the prefrontal and anterior cingulate cortex to maintain performance during inflammation ([@B34]). If increased connectivity is required to maintain performance during inflammation, then inflammatory insults may unmask vulnerability, when evolving neurodegeneration impairs connectivity ([@B19]). The ME7 model of delirium during dementia has, until now, been an exemplar for an inflammatory hypersensitivity ([@B53]), but these data show that these mice are also more vulnerable to "bioenergetic stressors." Despite equivalent reductions in blood and CSF glucose, NBH animals are resilient to hypoglycemia-induced cognitive impairment but ME7 animals are vulnerable, whether induced by LPS or by insulin.

The brain is a metabolically demanding organ and it may be adaptive, for survival, to minimize energy use in the brain and preserve autonomic function at the expense of higher cortical function. Engel and Romano proposed that delirium is driven by a failure to meet the brain\'s energy requirements, regardless of the underlying cause ([@B25]). Hypoglycemia is sufficient, alone, to produce delirium and EEG slowing, and this is reversed by glucose administration ([@B24]). Small CSF studies support the idea of metabolic disturbances during delirium: patients with delirium have elevated CSF lactate compared with non-delirious Alzheimer\'s disease controls ([@B8]) and \[^18^F\]FDG-PET studies show decreased glucose uptake ([@B32]). The posterior cingulate cortex, which is associated with attention and arousal, was particularly affected and disrupting energy metabolism here could be important in delirium.

Although hypoglycemia in mice is not precisely defined, the ME7 blood glucose concentrations here remained just above the clinical threshold for moderate hypoglycemia (3.9 mmol/l; [@B13]). Iatrogenic hypoglycemia is common in patients using insulin for diabetes ([@B12]) and is a major cause of emergency department admissions and adverse CNS effects in older patients ([@B65]). Significantly, our ME7 data suggest that even when blood glucose levels do not fall into classical hypoglycemic ranges, these changes have significant deleterious impacts on brain function in those with prior vulnerability.

Importantly glucose was not lower in the hip fracture patients studied here ([Fig. 6](#F6){ref-type="fig"}*A*). Both hypoglycemia and hyperglycemia increase risk for sepsis-associated encephalopathy ([@B68]), but hypoglycemia is less common. However, insulin insensitivity, and impaired glucose uptake, typically accompanies hyperglycemia-associated delirium. In humans, insulin resistance occurs on LPS ([@B1]), infection ([@B76]), and surgery ([@B74]). Microcirculatory failure and tissue hypoxia, common in sepsis ([@B38]), may also disrupt glucose oxidation and the elevated lactate and pyruvate in the current study might indicate a shift from normal aerobic to anaerobic glycolysis. Although dementia status is a major risk factor for delirium ([@B19]), the changes in lactate and LGR observed are not explained by existing dementia. The data are consistent with previously demonstrated associations between delirium and increased CSF lactate ([@B8]) and hypoxia ([@B70]).

Conclusion
==========

Reduced glucose availability is a major driver of LPS-induced suppression of spontaneous activity. In animals made vulnerable by evolving neurodegeneration, this decreased glucose is now sufficient to trigger acute cognitive dysfunction indicating that metabolic insufficiency underlies cognitive dysfunction in this animal model resembling delirium. A disruption of energy metabolism also occurs in delirium triggered by inflammatory trauma. Together, the findings indicate that acutely disrupted energy metabolism likely contributes to general behavioral changes associated with sickness but also to acute neuropsychiatric disorders such as delirium. Systemic inflammation produces disproportionate brain dysfunction when superimposed on the vulnerable brain, as is evident during bacterial sepsis and infections such as SARS-CoV-2 in older people. The appropriate supply of both oxygen and energy substrates to the brain becomes especially important in those with existing cognitive vulnerability. The current data should focus attention on bioenergetic mechanisms of acute brain failure during acute illness and hospitalization in older adults.
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